nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A7—Progesterone—uterine cancer	0.0716	0.17	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0716	0.17	CbGbCtD
Aripiprazole—CYP3A5—Progesterone—uterine cancer	0.0537	0.127	CbGbCtD
Aripiprazole—ABCB1—Progesterone—uterine cancer	0.035	0.083	CbGbCtD
Aripiprazole—CYP2D6—Progesterone—uterine cancer	0.0329	0.0782	CbGbCtD
Aripiprazole—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0316	0.0751	CbGbCtD
Aripiprazole—ABCB1—Dactinomycin—uterine cancer	0.0277	0.0658	CbGbCtD
Aripiprazole—CYP3A5—Etoposide—uterine cancer	0.024	0.0571	CbGbCtD
Aripiprazole—CYP3A4—Progesterone—uterine cancer	0.021	0.0497	CbGbCtD
Aripiprazole—ABCB1—Etoposide—uterine cancer	0.0156	0.0371	CbGbCtD
Aripiprazole—CHRM3—ureter—uterine cancer	0.0108	0.0862	CbGeAlD
Aripiprazole—ABCB1—Doxorubicin—uterine cancer	0.0107	0.0253	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—uterine cancer	0.0101	0.0239	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—uterine cancer	0.00938	0.0222	CbGbCtD
Aripiprazole—CHRM3—muscle of abdomen—uterine cancer	0.00781	0.0621	CbGeAlD
Aripiprazole—H1F0—semen—uterine cancer	0.00778	0.0619	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—uterine cancer	0.00639	0.0152	CbGbCtD
Aripiprazole—H1F0—oviduct—uterine cancer	0.00571	0.0454	CbGeAlD
Aripiprazole—HTR1E—myometrium—uterine cancer	0.00309	0.0246	CbGeAlD
Aripiprazole—HTR1B—artery—uterine cancer	0.00302	0.0241	CbGeAlD
Aripiprazole—HTR1D—artery—uterine cancer	0.00293	0.0233	CbGeAlD
Aripiprazole—HTR7—artery—uterine cancer	0.00233	0.0185	CbGeAlD
Aripiprazole—CHRM3—exocrine gland—uterine cancer	0.00214	0.017	CbGeAlD
Aripiprazole—H1F0—myometrium—uterine cancer	0.00183	0.0145	CbGeAlD
Aripiprazole—CHRM5—epithelium—uterine cancer	0.00166	0.0132	CbGeAlD
Aripiprazole—HTR1E—female gonad—uterine cancer	0.00164	0.013	CbGeAlD
Aripiprazole—HTR2A—artery—uterine cancer	0.00145	0.0116	CbGeAlD
Aripiprazole—H1F0—uterine cervix—uterine cancer	0.00142	0.0113	CbGeAlD
Aripiprazole—ADRA1B—renal system—uterine cancer	0.00141	0.0112	CbGeAlD
Aripiprazole—H1F0—smooth muscle tissue—uterine cancer	0.00138	0.011	CbGeAlD
Aripiprazole—DRD5—female reproductive system—uterine cancer	0.00138	0.0109	CbGeAlD
Aripiprazole—H1F0—decidua—uterine cancer	0.00135	0.0108	CbGeAlD
Aripiprazole—H1F0—renal system—uterine cancer	0.00133	0.0106	CbGeAlD
Aripiprazole—HTR2B—myometrium—uterine cancer	0.00132	0.0105	CbGeAlD
Aripiprazole—H1F0—endometrium—uterine cancer	0.00129	0.0102	CbGeAlD
Aripiprazole—DRD5—female gonad—uterine cancer	0.00125	0.00996	CbGeAlD
Aripiprazole—H1F0—mammalian vulva—uterine cancer	0.00124	0.00989	CbGeAlD
Aripiprazole—H1F0—uterus—uterine cancer	0.00118	0.00942	CbGeAlD
Aripiprazole—H1F0—female reproductive system—uterine cancer	0.00106	0.00847	CbGeAlD
Aripiprazole—KCNH2—myometrium—uterine cancer	0.00105	0.00835	CbGeAlD
Aripiprazole—ADRA2C—myometrium—uterine cancer	0.00104	0.00824	CbGeAlD
Aripiprazole—HTR2B—uterine cervix—uterine cancer	0.00102	0.00814	CbGeAlD
Aripiprazole—HTR2B—smooth muscle tissue—uterine cancer	0.000995	0.00791	CbGeAlD
Aripiprazole—HTR2B—decidua—uterine cancer	0.000976	0.00776	CbGeAlD
Aripiprazole—H1F0—female gonad—uterine cancer	0.000969	0.0077	CbGeAlD
Aripiprazole—H1F0—vagina—uterine cancer	0.000963	0.00766	CbGeAlD
Aripiprazole—HTR2B—endometrium—uterine cancer	0.000926	0.00737	CbGeAlD
Aripiprazole—CHRM3—smooth muscle tissue—uterine cancer	0.000895	0.00712	CbGeAlD
Aripiprazole—HTR7—epithelium—uterine cancer	0.000885	0.00703	CbGeAlD
Aripiprazole—CHRM3—renal system—uterine cancer	0.000862	0.00685	CbGeAlD
Aripiprazole—HTR1A—renal system—uterine cancer	0.000859	0.00683	CbGeAlD
Aripiprazole—HTR2B—uterus—uterine cancer	0.000854	0.00679	CbGeAlD
Aripiprazole—ADRA1A—epithelium—uterine cancer	0.000853	0.00678	CbGeAlD
Aripiprazole—HTR7—smooth muscle tissue—uterine cancer	0.000852	0.00678	CbGeAlD
Aripiprazole—HTR1B—female reproductive system—uterine cancer	0.000852	0.00677	CbGeAlD
Aripiprazole—HRH1—myometrium—uterine cancer	0.000842	0.00669	CbGeAlD
Aripiprazole—ADRA2A—myometrium—uterine cancer	0.000827	0.00657	CbGeAlD
Aripiprazole—HTR1D—female reproductive system—uterine cancer	0.000825	0.00656	CbGeAlD
Aripiprazole—HTR7—renal system—uterine cancer	0.000821	0.00652	CbGeAlD
Aripiprazole—KCNH2—uterine cervix—uterine cancer	0.000817	0.0065	CbGeAlD
Aripiprazole—HTR2C—female reproductive system—uterine cancer	0.000817	0.0065	CbGeAlD
Aripiprazole—ADRA2C—uterine cervix—uterine cancer	0.000806	0.00641	CbGeAlD
Aripiprazole—ADRB1—female reproductive system—uterine cancer	0.000802	0.00637	CbGeAlD
Aripiprazole—ADRA1A—renal system—uterine cancer	0.000791	0.00629	CbGeAlD
Aripiprazole—SLC6A4—female reproductive system—uterine cancer	0.000774	0.00616	CbGeAlD
Aripiprazole—CHRM1—female reproductive system—uterine cancer	0.000771	0.00613	CbGeAlD
Aripiprazole—ADRA2C—decidua—uterine cancer	0.000768	0.00611	CbGeAlD
Aripiprazole—HTR2B—female reproductive system—uterine cancer	0.000767	0.0061	CbGeAlD
Aripiprazole—KCNH2—renal system—uterine cancer	0.000764	0.00608	CbGeAlD
Aripiprazole—ADRA2C—renal system—uterine cancer	0.000754	0.006	CbGeAlD
Aripiprazole—KCNH2—endometrium—uterine cancer	0.000739	0.00588	CbGeAlD
Aripiprazole—ADRA2C—endometrium—uterine cancer	0.000729	0.0058	CbGeAlD
Aripiprazole—ADRA2C—mammalian vulva—uterine cancer	0.000705	0.00561	CbGeAlD
Aripiprazole—HTR2B—vagina—uterine cancer	0.000694	0.00552	CbGeAlD
Aripiprazole—CHRM3—female reproductive system—uterine cancer	0.00069	0.00549	CbGeAlD
Aripiprazole—KCNH2—uterus—uterine cancer	0.000681	0.00541	CbGeAlD
Aripiprazole—CYP3A5—uterine cervix—uterine cancer	0.000675	0.00536	CbGeAlD
Aripiprazole—ADRA2C—uterus—uterine cancer	0.000672	0.00534	CbGeAlD
Aripiprazole—HRH1—epithelium—uterine cancer	0.00066	0.00525	CbGeAlD
Aripiprazole—HTR7—female reproductive system—uterine cancer	0.000657	0.00522	CbGeAlD
Aripiprazole—HRH1—uterine cervix—uterine cancer	0.000655	0.00521	CbGeAlD
Aripiprazole—ADRA2A—uterine cervix—uterine cancer	0.000643	0.00511	CbGeAlD
Aripiprazole—HRH1—smooth muscle tissue—uterine cancer	0.000636	0.00506	CbGeAlD
Aripiprazole—CYP3A5—renal system—uterine cancer	0.000631	0.00502	CbGeAlD
Aripiprazole—CHRM3—female gonad—uterine cancer	0.000628	0.00499	CbGeAlD
Aripiprazole—HRH1—decidua—uterine cancer	0.000624	0.00496	CbGeAlD
Aripiprazole—H1F0—lymph node—uterine cancer	0.000623	0.00495	CbGeAlD
Aripiprazole—ADRA2A—decidua—uterine cancer	0.000613	0.00487	CbGeAlD
Aripiprazole—KCNH2—female reproductive system—uterine cancer	0.000612	0.00487	CbGeAlD
Aripiprazole—HRH1—endometrium—uterine cancer	0.000592	0.00471	CbGeAlD
Aripiprazole—ADRA2A—endometrium—uterine cancer	0.000582	0.00463	CbGeAlD
Aripiprazole—HRH1—mammalian vulva—uterine cancer	0.000573	0.00456	CbGeAlD
Aripiprazole—ADRA2A—mammalian vulva—uterine cancer	0.000563	0.00447	CbGeAlD
Aripiprazole—KCNH2—female gonad—uterine cancer	0.000557	0.00443	CbGeAlD
Aripiprazole—KCNH2—vagina—uterine cancer	0.000554	0.0044	CbGeAlD
Aripiprazole—HTR2A—epithelium—uterine cancer	0.000552	0.00439	CbGeAlD
Aripiprazole—ADRA2C—female gonad—uterine cancer	0.00055	0.00437	CbGeAlD
Aripiprazole—ADRA2C—vagina—uterine cancer	0.000546	0.00434	CbGeAlD
Aripiprazole—ADRA2A—uterus—uterine cancer	0.000536	0.00426	CbGeAlD
Aripiprazole—HTR2A—smooth muscle tissue—uterine cancer	0.000532	0.00423	CbGeAlD
Aripiprazole—HTR2A—renal system—uterine cancer	0.000512	0.00407	CbGeAlD
Aripiprazole—HRH1—female reproductive system—uterine cancer	0.000491	0.0039	CbGeAlD
Aripiprazole—ADRA2A—female reproductive system—uterine cancer	0.000482	0.00383	CbGeAlD
Aripiprazole—CYP3A4—renal system—uterine cancer	0.000474	0.00377	CbGeAlD
Aripiprazole—CYP2D6—renal system—uterine cancer	0.000466	0.00371	CbGeAlD
Aripiprazole—ABCB1—myometrium—uterine cancer	0.000461	0.00366	CbGeAlD
Aripiprazole—CYP3A5—female gonad—uterine cancer	0.00046	0.00366	CbGeAlD
Aripiprazole—CYP3A5—vagina—uterine cancer	0.000457	0.00364	CbGeAlD
Aripiprazole—HTR2B—lymph node—uterine cancer	0.000449	0.00357	CbGeAlD
Aripiprazole—HRH1—female gonad—uterine cancer	0.000446	0.00355	CbGeAlD
Aripiprazole—HRH1—vagina—uterine cancer	0.000444	0.00353	CbGeAlD
Aripiprazole—ADRA2A—female gonad—uterine cancer	0.000439	0.00349	CbGeAlD
Aripiprazole—ADRA2A—vagina—uterine cancer	0.000436	0.00347	CbGeAlD
Aripiprazole—HTR2A—female reproductive system—uterine cancer	0.00041	0.00326	CbGeAlD
Aripiprazole—CYP3A4—female reproductive system—uterine cancer	0.000379	0.00302	CbGeAlD
Aripiprazole—CYP2D6—female reproductive system—uterine cancer	0.000373	0.00297	CbGeAlD
Aripiprazole—HTR2A—vagina—uterine cancer	0.000371	0.00295	CbGeAlD
Aripiprazole—ABCB1—epithelium—uterine cancer	0.000361	0.00287	CbGeAlD
Aripiprazole—ABCB1—uterine cervix—uterine cancer	0.000358	0.00285	CbGeAlD
Aripiprazole—KCNH2—lymph node—uterine cancer	0.000358	0.00285	CbGeAlD
Aripiprazole—ADRA2C—lymph node—uterine cancer	0.000353	0.00281	CbGeAlD
Aripiprazole—ABCB1—decidua—uterine cancer	0.000341	0.00272	CbGeAlD
Aripiprazole—CYP2D6—female gonad—uterine cancer	0.00034	0.0027	CbGeAlD
Aripiprazole—ABCB1—renal system—uterine cancer	0.000335	0.00267	CbGeAlD
Aripiprazole—ABCB1—endometrium—uterine cancer	0.000324	0.00258	CbGeAlD
Aripiprazole—ABCB1—mammalian vulva—uterine cancer	0.000314	0.00249	CbGeAlD
Aripiprazole—ABCB1—uterus—uterine cancer	0.000299	0.00238	CbGeAlD
Aripiprazole—HRH1—lymph node—uterine cancer	0.000287	0.00228	CbGeAlD
Aripiprazole—ADRA2A—lymph node—uterine cancer	0.000282	0.00224	CbGeAlD
Aripiprazole—ABCB1—female reproductive system—uterine cancer	0.000269	0.00214	CbGeAlD
Aripiprazole—ABCB1—female gonad—uterine cancer	0.000244	0.00194	CbGeAlD
Aripiprazole—ABCB1—vagina—uterine cancer	0.000243	0.00193	CbGeAlD
Aripiprazole—ABCB1—lymph node—uterine cancer	0.000157	0.00125	CbGeAlD
Aripiprazole—Asthma—Doxorubicin—uterine cancer	0.000106	0.000259	CcSEcCtD
Aripiprazole—Dysphagia—Doxorubicin—uterine cancer	0.000106	0.000259	CcSEcCtD
Aripiprazole—Pollakiuria—Epirubicin—uterine cancer	0.000106	0.000259	CcSEcCtD
Aripiprazole—Eosinophilia—Doxorubicin—uterine cancer	0.000105	0.000257	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Epirubicin—uterine cancer	0.000104	0.000256	CcSEcCtD
Aripiprazole—Paraesthesia—Etoposide—uterine cancer	0.000104	0.000255	CcSEcCtD
Aripiprazole—Weight increased—Epirubicin—uterine cancer	0.000104	0.000255	CcSEcCtD
Aripiprazole—Pancreatitis—Doxorubicin—uterine cancer	0.000104	0.000254	CcSEcCtD
Aripiprazole—Weight decreased—Epirubicin—uterine cancer	0.000103	0.000253	CcSEcCtD
Aripiprazole—Dyspnoea—Etoposide—uterine cancer	0.000103	0.000253	CcSEcCtD
Aripiprazole—Hyperglycaemia—Epirubicin—uterine cancer	0.000103	0.000253	CcSEcCtD
Aripiprazole—Somnolence—Etoposide—uterine cancer	0.000103	0.000253	CcSEcCtD
Aripiprazole—Angina pectoris—Doxorubicin—uterine cancer	0.000103	0.000253	CcSEcCtD
Aripiprazole—Pneumonia—Epirubicin—uterine cancer	0.000102	0.000251	CcSEcCtD
Aripiprazole—Infestation NOS—Epirubicin—uterine cancer	0.000102	0.00025	CcSEcCtD
Aripiprazole—Infestation—Epirubicin—uterine cancer	0.000102	0.00025	CcSEcCtD
Aripiprazole—Vomiting—Dactinomycin—uterine cancer	0.000102	0.00025	CcSEcCtD
Aripiprazole—Rash—Dactinomycin—uterine cancer	0.000101	0.000248	CcSEcCtD
Aripiprazole—Decreased appetite—Etoposide—uterine cancer	0.000101	0.000247	CcSEcCtD
Aripiprazole—Renal failure—Epirubicin—uterine cancer	0.0001	0.000246	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Etoposide—uterine cancer	0.0001	0.000245	CcSEcCtD
Aripiprazole—Fatigue—Etoposide—uterine cancer	9.99e-05	0.000245	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Epirubicin—uterine cancer	9.99e-05	0.000245	CcSEcCtD
Aripiprazole—Stomatitis—Epirubicin—uterine cancer	9.93e-05	0.000244	CcSEcCtD
Aripiprazole—Jaundice—Epirubicin—uterine cancer	9.93e-05	0.000244	CcSEcCtD
Aripiprazole—Pain—Etoposide—uterine cancer	9.91e-05	0.000243	CcSEcCtD
Aripiprazole—Constipation—Etoposide—uterine cancer	9.91e-05	0.000243	CcSEcCtD
Aripiprazole—Conjunctivitis—Epirubicin—uterine cancer	9.9e-05	0.000243	CcSEcCtD
Aripiprazole—Urinary tract infection—Epirubicin—uterine cancer	9.9e-05	0.000243	CcSEcCtD
Aripiprazole—Neutropenia—Doxorubicin—uterine cancer	9.89e-05	0.000242	CcSEcCtD
Aripiprazole—Dysuria—Doxorubicin—uterine cancer	9.89e-05	0.000242	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.83e-05	0.000241	CcSEcCtD
Aripiprazole—Sweating—Epirubicin—uterine cancer	9.77e-05	0.00024	CcSEcCtD
Aripiprazole—Pollakiuria—Doxorubicin—uterine cancer	9.77e-05	0.000239	CcSEcCtD
Aripiprazole—Haematuria—Epirubicin—uterine cancer	9.71e-05	0.000238	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Doxorubicin—uterine cancer	9.65e-05	0.000237	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Epirubicin—uterine cancer	9.64e-05	0.000236	CcSEcCtD
Aripiprazole—Weight increased—Doxorubicin—uterine cancer	9.62e-05	0.000236	CcSEcCtD
Aripiprazole—Epistaxis—Epirubicin—uterine cancer	9.61e-05	0.000236	CcSEcCtD
Aripiprazole—Weight decreased—Doxorubicin—uterine cancer	9.57e-05	0.000235	CcSEcCtD
Aripiprazole—Sinusitis—Epirubicin—uterine cancer	9.56e-05	0.000234	CcSEcCtD
Aripiprazole—Feeling abnormal—Etoposide—uterine cancer	9.55e-05	0.000234	CcSEcCtD
Aripiprazole—Hyperglycaemia—Doxorubicin—uterine cancer	9.54e-05	0.000234	CcSEcCtD
Aripiprazole—Nausea—Dactinomycin—uterine cancer	9.51e-05	0.000233	CcSEcCtD
Aripiprazole—Agranulocytosis—Epirubicin—uterine cancer	9.51e-05	0.000233	CcSEcCtD
Aripiprazole—Pneumonia—Doxorubicin—uterine cancer	9.48e-05	0.000233	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Etoposide—uterine cancer	9.48e-05	0.000232	CcSEcCtD
Aripiprazole—Infestation—Doxorubicin—uterine cancer	9.43e-05	0.000231	CcSEcCtD
Aripiprazole—Infestation NOS—Doxorubicin—uterine cancer	9.43e-05	0.000231	CcSEcCtD
Aripiprazole—Bradycardia—Epirubicin—uterine cancer	9.31e-05	0.000228	CcSEcCtD
Aripiprazole—Renal failure—Doxorubicin—uterine cancer	9.27e-05	0.000227	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Doxorubicin—uterine cancer	9.24e-05	0.000227	CcSEcCtD
Aripiprazole—Urticaria—Etoposide—uterine cancer	9.21e-05	0.000226	CcSEcCtD
Aripiprazole—Haemoglobin—Epirubicin—uterine cancer	9.19e-05	0.000225	CcSEcCtD
Aripiprazole—Jaundice—Doxorubicin—uterine cancer	9.19e-05	0.000225	CcSEcCtD
Aripiprazole—Stomatitis—Doxorubicin—uterine cancer	9.19e-05	0.000225	CcSEcCtD
Aripiprazole—Rhinitis—Epirubicin—uterine cancer	9.17e-05	0.000225	CcSEcCtD
Aripiprazole—Abdominal pain—Etoposide—uterine cancer	9.16e-05	0.000225	CcSEcCtD
Aripiprazole—Body temperature increased—Etoposide—uterine cancer	9.16e-05	0.000225	CcSEcCtD
Aripiprazole—Urinary tract infection—Doxorubicin—uterine cancer	9.16e-05	0.000225	CcSEcCtD
Aripiprazole—Conjunctivitis—Doxorubicin—uterine cancer	9.16e-05	0.000225	CcSEcCtD
Aripiprazole—Haemorrhage—Epirubicin—uterine cancer	9.15e-05	0.000224	CcSEcCtD
Aripiprazole—Hepatitis—Epirubicin—uterine cancer	9.15e-05	0.000224	CcSEcCtD
Aripiprazole—Hypoaesthesia—Epirubicin—uterine cancer	9.1e-05	0.000223	CcSEcCtD
Aripiprazole—Pharyngitis—Epirubicin—uterine cancer	9.08e-05	0.000223	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—uterine cancer	9.04e-05	0.000222	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—uterine cancer	9.03e-05	0.000221	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—uterine cancer	9.01e-05	0.000221	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—uterine cancer	8.99e-05	0.00022	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—uterine cancer	8.99e-05	0.00022	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—uterine cancer	8.97e-05	0.00022	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—uterine cancer	8.92e-05	0.000219	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—uterine cancer	8.89e-05	0.000218	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—uterine cancer	8.84e-05	0.000217	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—uterine cancer	8.81e-05	0.000216	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—uterine cancer	8.8e-05	0.000216	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—uterine cancer	8.62e-05	0.000211	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—uterine cancer	8.55e-05	0.00021	CcSEcCtD
Aripiprazole—Hypersensitivity—Etoposide—uterine cancer	8.54e-05	0.000209	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—uterine cancer	8.53e-05	0.000209	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—uterine cancer	8.51e-05	0.000209	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—uterine cancer	8.49e-05	0.000208	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—uterine cancer	8.49e-05	0.000208	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—uterine cancer	8.48e-05	0.000208	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—uterine cancer	8.46e-05	0.000208	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—uterine cancer	8.46e-05	0.000208	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—uterine cancer	8.42e-05	0.000206	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—uterine cancer	8.4e-05	0.000206	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—uterine cancer	8.36e-05	0.000205	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—uterine cancer	8.34e-05	0.000204	CcSEcCtD
Aripiprazole—Asthenia—Etoposide—uterine cancer	8.32e-05	0.000204	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—uterine cancer	8.32e-05	0.000204	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—uterine cancer	8.3e-05	0.000203	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—uterine cancer	8.3e-05	0.000203	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—uterine cancer	8.26e-05	0.000203	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—uterine cancer	8.24e-05	0.000202	CcSEcCtD
Aripiprazole—Chills—Epirubicin—uterine cancer	8.21e-05	0.000201	CcSEcCtD
Aripiprazole—Pruritus—Etoposide—uterine cancer	8.2e-05	0.000201	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—uterine cancer	8.16e-05	0.0002	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—uterine cancer	8.08e-05	0.000198	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—uterine cancer	8.01e-05	0.000196	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—uterine cancer	7.96e-05	0.000195	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—uterine cancer	7.96e-05	0.000195	CcSEcCtD
Aripiprazole—Diarrhoea—Etoposide—uterine cancer	7.93e-05	0.000194	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—uterine cancer	7.91e-05	0.000194	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—uterine cancer	7.89e-05	0.000193	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—uterine cancer	7.85e-05	0.000193	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—uterine cancer	7.85e-05	0.000193	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—uterine cancer	7.85e-05	0.000192	CcSEcCtD
Aripiprazole—Tension—Epirubicin—uterine cancer	7.81e-05	0.000192	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—uterine cancer	7.8e-05	0.000191	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—uterine cancer	7.73e-05	0.00019	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—uterine cancer	7.7e-05	0.000189	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—uterine cancer	7.68e-05	0.000188	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—uterine cancer	7.67e-05	0.000188	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—uterine cancer	7.66e-05	0.000188	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—uterine cancer	7.64e-05	0.000187	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—uterine cancer	7.63e-05	0.000187	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—uterine cancer	7.59e-05	0.000186	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—uterine cancer	7.5e-05	0.000184	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—uterine cancer	7.48e-05	0.000183	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—uterine cancer	7.41e-05	0.000182	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—uterine cancer	7.39e-05	0.000181	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—uterine cancer	7.37e-05	0.000181	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—uterine cancer	7.37e-05	0.000181	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—uterine cancer	7.37e-05	0.000181	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—uterine cancer	7.36e-05	0.00018	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—uterine cancer	7.32e-05	0.000179	CcSEcCtD
Aripiprazole—Rash—Etoposide—uterine cancer	7.31e-05	0.000179	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—uterine cancer	7.3e-05	0.000179	CcSEcCtD
Aripiprazole—Headache—Etoposide—uterine cancer	7.26e-05	0.000178	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—uterine cancer	7.26e-05	0.000178	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—uterine cancer	7.23e-05	0.000177	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—uterine cancer	7.21e-05	0.000177	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—uterine cancer	7.18e-05	0.000176	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—uterine cancer	7.16e-05	0.000175	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—uterine cancer	7.15e-05	0.000175	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—uterine cancer	7.14e-05	0.000175	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—uterine cancer	7.13e-05	0.000175	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—uterine cancer	7.13e-05	0.000175	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—uterine cancer	7.08e-05	0.000174	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—uterine cancer	7.04e-05	0.000173	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—uterine cancer	7e-05	0.000172	CcSEcCtD
Aripiprazole—Cough—Epirubicin—uterine cancer	6.95e-05	0.00017	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—uterine cancer	6.94e-05	0.00017	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—uterine cancer	6.9e-05	0.000169	CcSEcCtD
Aripiprazole—Nausea—Etoposide—uterine cancer	6.89e-05	0.000169	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—uterine cancer	6.87e-05	0.000169	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—uterine cancer	6.84e-05	0.000168	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—uterine cancer	6.81e-05	0.000167	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—uterine cancer	6.78e-05	0.000166	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—uterine cancer	6.78e-05	0.000166	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—uterine cancer	6.78e-05	0.000166	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—uterine cancer	6.77e-05	0.000166	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—uterine cancer	6.76e-05	0.000166	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.73e-05	0.000165	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—uterine cancer	6.7e-05	0.000164	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—uterine cancer	6.64e-05	0.000163	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—uterine cancer	6.63e-05	0.000163	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—uterine cancer	6.62e-05	0.000162	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—uterine cancer	6.61e-05	0.000162	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—uterine cancer	6.59e-05	0.000162	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—uterine cancer	6.55e-05	0.000161	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—uterine cancer	6.51e-05	0.00016	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—uterine cancer	6.5e-05	0.000159	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—uterine cancer	6.5e-05	0.000159	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—uterine cancer	6.48e-05	0.000159	CcSEcCtD
Aripiprazole—Infection—Epirubicin—uterine cancer	6.46e-05	0.000158	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—uterine cancer	6.43e-05	0.000158	CcSEcCtD
Aripiprazole—Shock—Epirubicin—uterine cancer	6.39e-05	0.000157	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—uterine cancer	6.38e-05	0.000157	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—uterine cancer	6.37e-05	0.000156	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—uterine cancer	6.36e-05	0.000156	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—uterine cancer	6.36e-05	0.000156	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—uterine cancer	6.34e-05	0.000156	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—uterine cancer	6.31e-05	0.000155	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—uterine cancer	6.28e-05	0.000154	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—uterine cancer	6.27e-05	0.000154	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—uterine cancer	6.27e-05	0.000154	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—uterine cancer	6.27e-05	0.000154	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—uterine cancer	6.25e-05	0.000153	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.23e-05	0.000153	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—uterine cancer	6.2e-05	0.000152	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—uterine cancer	6.19e-05	0.000152	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—uterine cancer	6.13e-05	0.00015	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—uterine cancer	6.07e-05	0.000149	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—uterine cancer	6.06e-05	0.000149	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—uterine cancer	6.01e-05	0.000147	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—uterine cancer	6.01e-05	0.000147	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—uterine cancer	5.97e-05	0.000146	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.92e-05	0.000145	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—uterine cancer	5.92e-05	0.000145	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—uterine cancer	5.9e-05	0.000145	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—uterine cancer	5.89e-05	0.000144	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—uterine cancer	5.88e-05	0.000144	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—uterine cancer	5.87e-05	0.000144	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—uterine cancer	5.84e-05	0.000143	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—uterine cancer	5.84e-05	0.000143	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—uterine cancer	5.81e-05	0.000143	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—uterine cancer	5.79e-05	0.000142	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—uterine cancer	5.78e-05	0.000142	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—uterine cancer	5.73e-05	0.000141	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—uterine cancer	5.72e-05	0.00014	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—uterine cancer	5.65e-05	0.000139	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—uterine cancer	5.62e-05	0.000138	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—uterine cancer	5.61e-05	0.000138	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—uterine cancer	5.6e-05	0.000137	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—uterine cancer	5.56e-05	0.000136	CcSEcCtD
Aripiprazole—Pain—Epirubicin—uterine cancer	5.56e-05	0.000136	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.48e-05	0.000134	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—uterine cancer	5.44e-05	0.000133	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—uterine cancer	5.4e-05	0.000132	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—uterine cancer	5.36e-05	0.000131	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—uterine cancer	5.35e-05	0.000131	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—uterine cancer	5.35e-05	0.000131	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—uterine cancer	5.31e-05	0.00013	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—uterine cancer	5.29e-05	0.00013	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—uterine cancer	5.23e-05	0.000128	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.19e-05	0.000127	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—uterine cancer	5.18e-05	0.000127	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—uterine cancer	5.16e-05	0.000127	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—uterine cancer	5.14e-05	0.000126	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—uterine cancer	5.14e-05	0.000126	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—uterine cancer	5.14e-05	0.000126	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—uterine cancer	5.14e-05	0.000126	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—uterine cancer	4.95e-05	0.000121	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—uterine cancer	4.92e-05	0.000121	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—uterine cancer	4.79e-05	0.000117	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—uterine cancer	4.78e-05	0.000117	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—uterine cancer	4.75e-05	0.000117	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—uterine cancer	4.75e-05	0.000117	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—uterine cancer	4.66e-05	0.000114	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—uterine cancer	4.6e-05	0.000113	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—uterine cancer	4.45e-05	0.000109	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—uterine cancer	4.43e-05	0.000109	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—uterine cancer	4.31e-05	0.000106	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—uterine cancer	4.3e-05	0.000105	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—uterine cancer	4.25e-05	0.000104	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—uterine cancer	4.13e-05	0.000101	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—uterine cancer	4.11e-05	0.000101	CcSEcCtD
Aripiprazole—Rash—Epirubicin—uterine cancer	4.1e-05	0.0001	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—uterine cancer	4.09e-05	0.0001	CcSEcCtD
Aripiprazole—Headache—Epirubicin—uterine cancer	4.07e-05	9.98e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—uterine cancer	3.98e-05	9.75e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—uterine cancer	3.86e-05	9.46e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—uterine cancer	3.82e-05	9.37e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—uterine cancer	3.79e-05	9.3e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—uterine cancer	3.79e-05	9.29e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—uterine cancer	3.77e-05	9.24e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—uterine cancer	3.57e-05	8.76e-05	CcSEcCtD
Aripiprazole—CHRM4—Signaling Pathways—KRAS—uterine cancer	4.53e-06	0.000101	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	4.52e-06	0.000101	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—EP300—uterine cancer	4.52e-06	0.0001	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCL8—uterine cancer	4.52e-06	0.0001	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—AKT1—uterine cancer	4.51e-06	0.0001	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—AKT1—uterine cancer	4.49e-06	9.98e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HRAS—uterine cancer	4.49e-06	9.98e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PTEN—uterine cancer	4.48e-06	9.95e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCL8—uterine cancer	4.45e-06	9.88e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCL8—uterine cancer	4.44e-06	9.86e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.43e-06	9.85e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—STK11—uterine cancer	4.43e-06	9.85e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCL8—uterine cancer	4.42e-06	9.83e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—HRAS—uterine cancer	4.42e-06	9.82e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EP300—uterine cancer	4.41e-06	9.81e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1B—uterine cancer	4.41e-06	9.81e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—PIK3CA—uterine cancer	4.41e-06	9.8e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCL8—uterine cancer	4.41e-06	9.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HRAS—uterine cancer	4.41e-06	9.8e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PTEN—uterine cancer	4.41e-06	9.8e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—PIK3CA—uterine cancer	4.41e-06	9.79e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HRAS—uterine cancer	4.39e-06	9.77e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EP300—uterine cancer	4.39e-06	9.76e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—KRAS—uterine cancer	4.38e-06	9.74e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HRAS—uterine cancer	4.38e-06	9.74e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—PIK3CA—uterine cancer	4.38e-06	9.73e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—VEGFA—uterine cancer	4.37e-06	9.71e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	4.37e-06	9.71e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCL8—uterine cancer	4.37e-06	9.7e-05	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—AKT1—uterine cancer	4.36e-06	9.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	4.35e-06	9.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PTEN—uterine cancer	4.35e-06	9.67e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	4.34e-06	9.66e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	4.34e-06	9.65e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HRAS—uterine cancer	4.34e-06	9.64e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—KRAS—uterine cancer	4.34e-06	9.64e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1B—uterine cancer	4.33e-06	9.63e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	4.33e-06	9.63e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	4.32e-06	9.61e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	4.32e-06	9.6e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—NRAS—uterine cancer	4.32e-06	9.6e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1B—uterine cancer	4.3e-06	9.57e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	4.3e-06	9.56e-05	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	4.29e-06	9.55e-05	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—AKT1—uterine cancer	4.29e-06	9.53e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	4.29e-06	9.53e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—NRAS—uterine cancer	4.28e-06	9.51e-05	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	4.27e-06	9.5e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EP300—uterine cancer	4.27e-06	9.49e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—uterine cancer	4.27e-06	9.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	4.27e-06	9.48e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	4.26e-06	9.48e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—uterine cancer	4.26e-06	9.47e-05	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—AKT1—uterine cancer	4.26e-06	9.47e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	4.25e-06	9.45e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—uterine cancer	4.23e-06	9.41e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—PIK3CA—uterine cancer	4.22e-06	9.37e-05	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	4.22e-06	9.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	4.21e-06	9.35e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EP300—uterine cancer	4.2e-06	9.34e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—VEGFA—uterine cancer	4.18e-06	9.29e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CTNNB1—uterine cancer	4.17e-06	9.27e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—PIK3CA—uterine cancer	4.16e-06	9.25e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—VEGFA—uterine cancer	4.16e-06	9.24e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—EP300—uterine cancer	4.15e-06	9.22e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—uterine cancer	4.15e-06	9.22e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—KRAS—uterine cancer	4.13e-06	9.19e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—NRAS—uterine cancer	4.13e-06	9.18e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—NRAS—uterine cancer	4.11e-06	9.13e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	4.1e-06	9.12e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CTNNB1—uterine cancer	4.09e-06	9.1e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—uterine cancer	4.08e-06	9.07e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	4.08e-06	9.07e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—uterine cancer	4.08e-06	9.07e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—KRAS—uterine cancer	4.08e-06	9.06e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—uterine cancer	4.08e-06	9.06e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CTNNB1—uterine cancer	4.07e-06	9.04e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PTEN—uterine cancer	4.06e-06	9.03e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—uterine cancer	4.05e-06	9e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	4.04e-06	8.99e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	4.04e-06	8.99e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	4.03e-06	8.95e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—PIK3CA—uterine cancer	4.03e-06	8.95e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—uterine cancer	4.02e-06	8.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	4.02e-06	8.93e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	4.02e-06	8.93e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PTEN—uterine cancer	4e-06	8.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NRAS—uterine cancer	3.99e-06	8.88e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PTEN—uterine cancer	3.99e-06	8.87e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTEN—uterine cancer	3.99e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—uterine cancer	3.98e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	3.98e-06	8.85e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTEN—uterine cancer	3.98e-06	8.84e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—uterine cancer	3.96e-06	8.81e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—uterine cancer	3.96e-06	8.81e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTEN—uterine cancer	3.96e-06	8.81e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	3.95e-06	8.78e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NRAS—uterine cancer	3.93e-06	8.74e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTEN—uterine cancer	3.93e-06	8.73e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTEN—uterine cancer	3.91e-06	8.7e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	3.91e-06	8.69e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—uterine cancer	3.9e-06	8.67e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—uterine cancer	3.9e-06	8.67e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—uterine cancer	3.89e-06	8.66e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—uterine cancer	3.89e-06	8.65e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.89e-06	8.65e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—uterine cancer	3.88e-06	8.62e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—uterine cancer	3.87e-06	8.61e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—uterine cancer	3.87e-06	8.6e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—uterine cancer	3.85e-06	8.57e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—uterine cancer	3.85e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—uterine cancer	3.83e-06	8.51e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	3.82e-06	8.49e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—uterine cancer	3.81e-06	8.48e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—uterine cancer	3.8e-06	8.46e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—uterine cancer	3.8e-06	8.45e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—uterine cancer	3.8e-06	8.44e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—uterine cancer	3.79e-06	8.43e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—uterine cancer	3.78e-06	8.4e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—uterine cancer	3.78e-06	8.4e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—uterine cancer	3.75e-06	8.33e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—uterine cancer	3.74e-06	8.32e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—uterine cancer	3.73e-06	8.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	3.73e-06	8.3e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—uterine cancer	3.72e-06	8.28e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—uterine cancer	3.71e-06	8.26e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—uterine cancer	3.69e-06	8.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—uterine cancer	3.68e-06	8.18e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—uterine cancer	3.67e-06	8.16e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—uterine cancer	3.67e-06	8.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—uterine cancer	3.64e-06	8.09e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—uterine cancer	3.62e-06	8.06e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—uterine cancer	3.62e-06	8.06e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—uterine cancer	3.61e-06	8.03e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—uterine cancer	3.6e-06	8.01e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—uterine cancer	3.6e-06	8.01e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—uterine cancer	3.6e-06	8e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—uterine cancer	3.59e-06	7.98e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—uterine cancer	3.58e-06	7.96e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—uterine cancer	3.58e-06	7.95e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—uterine cancer	3.57e-06	7.93e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—uterine cancer	3.56e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—uterine cancer	3.55e-06	7.9e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	3.55e-06	7.89e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—uterine cancer	3.55e-06	7.89e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—uterine cancer	3.55e-06	7.88e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—uterine cancer	3.54e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	3.54e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—uterine cancer	3.54e-06	7.86e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—uterine cancer	3.51e-06	7.81e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—uterine cancer	3.5e-06	7.78e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—uterine cancer	3.5e-06	7.78e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—uterine cancer	3.49e-06	7.76e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—uterine cancer	3.47e-06	7.71e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—uterine cancer	3.47e-06	7.7e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—uterine cancer	3.44e-06	7.66e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—uterine cancer	3.44e-06	7.64e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	3.41e-06	7.59e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—uterine cancer	3.4e-06	7.56e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—uterine cancer	3.38e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	3.38e-06	7.52e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—uterine cancer	3.34e-06	7.43e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—uterine cancer	3.33e-06	7.41e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—uterine cancer	3.3e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—uterine cancer	3.29e-06	7.31e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	3.29e-06	7.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—uterine cancer	3.27e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	3.26e-06	7.26e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—uterine cancer	3.25e-06	7.24e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	3.25e-06	7.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—uterine cancer	3.24e-06	7.21e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—uterine cancer	3.18e-06	7.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	3.16e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—uterine cancer	3.16e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—uterine cancer	3.16e-06	7.02e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—uterine cancer	3.14e-06	6.98e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—uterine cancer	3.13e-06	6.96e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—uterine cancer	3.12e-06	6.94e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	3.11e-06	6.91e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—uterine cancer	3.1e-06	6.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—uterine cancer	3.09e-06	6.86e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—uterine cancer	3.07e-06	6.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—uterine cancer	3.07e-06	6.82e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—uterine cancer	3.06e-06	6.81e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—uterine cancer	3.06e-06	6.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—uterine cancer	3.06e-06	6.79e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—uterine cancer	3.05e-06	6.79e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—uterine cancer	3.04e-06	6.77e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—uterine cancer	3.02e-06	6.71e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—uterine cancer	3.01e-06	6.7e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—uterine cancer	3.01e-06	6.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—uterine cancer	3.01e-06	6.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—uterine cancer	3.01e-06	6.68e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—uterine cancer	3e-06	6.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—uterine cancer	2.92e-06	6.5e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—uterine cancer	2.88e-06	6.39e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—uterine cancer	2.87e-06	6.38e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—uterine cancer	2.87e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—uterine cancer	2.83e-06	6.3e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	2.82e-06	6.27e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—uterine cancer	2.81e-06	6.26e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.81e-06	6.25e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	2.81e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—uterine cancer	2.8e-06	6.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—uterine cancer	2.79e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—uterine cancer	2.79e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—uterine cancer	2.77e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	2.77e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—uterine cancer	2.76e-06	6.14e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	2.76e-06	6.14e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—uterine cancer	2.73e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—uterine cancer	2.73e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—uterine cancer	2.72e-06	6.05e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—uterine cancer	2.71e-06	6.03e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—uterine cancer	2.71e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—uterine cancer	2.7e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—uterine cancer	2.68e-06	5.96e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—uterine cancer	2.67e-06	5.94e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—uterine cancer	2.67e-06	5.93e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—uterine cancer	2.65e-06	5.9e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—uterine cancer	2.65e-06	5.9e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—uterine cancer	2.61e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—uterine cancer	2.6e-06	5.79e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—uterine cancer	2.6e-06	5.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—uterine cancer	2.59e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—uterine cancer	2.58e-06	5.74e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	2.57e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—uterine cancer	2.56e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—uterine cancer	2.55e-06	5.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—uterine cancer	2.54e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—uterine cancer	2.51e-06	5.57e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—uterine cancer	2.48e-06	5.52e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—uterine cancer	2.37e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—uterine cancer	2.34e-06	5.21e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—uterine cancer	2.3e-06	5.12e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—uterine cancer	2.3e-06	5.11e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—uterine cancer	2.3e-06	5.11e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—uterine cancer	2.29e-06	5.09e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—uterine cancer	2.28e-06	5.08e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—uterine cancer	2.26e-06	5.03e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—uterine cancer	2.26e-06	5.02e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—uterine cancer	2.12e-06	4.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—uterine cancer	2.1e-06	4.66e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—uterine cancer	2e-06	4.45e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—uterine cancer	1.85e-06	4.12e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—uterine cancer	1.77e-06	3.93e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—uterine cancer	1.73e-06	3.85e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—uterine cancer	1.63e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.31e-06	2.91e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—uterine cancer	1.07e-06	2.37e-05	CbGpPWpGaD
